(Q60054208)

English

Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis

No description defined

In more languages

Statements

scholarly article

0 references

7 references

13 March 2019

14 March 2019

24 March 2019

2 August 2019

2 October 2019

30 January 2021

4 February 2021

0 references

Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis (English)

0 references

1 reference

2 August 2019

type 2 diabetes

3 references

2 August 2019

2 October 2019

4 February 2021

mechanism of action

1 reference

2 October 2019

dipeptidyl peptidase-4 inhibitors

1 reference

30 January 2021

author name string

Ben Wang

1

0 references

Yan Sun

2

0 references

Yiquan Sang

3

0 references

Xuekui Liu

4

0 references

Jun Liang

5

0 references

language of work or name

0 references

publication date

November 2018

0 references

1 November 2018

7 references

13 March 2019

14 March 2019

24 March 2019

2 August 2019

2 October 2019

30 January 2021

4 February 2021

7 references

13 March 2019

14 March 2019

24 March 2019

2 August 2019

2 October 2019

30 January 2021

4 February 2021

97

0 references

46

0 references

e12633

0 references

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

7 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

14 March 2019

Europe PubMed Central

24 March 2019

Europe PubMed Central

2 August 2019

Europe PubMed Central

2 October 2019

Europe PubMed Central

30 January 2021

Europe PubMed Central

4 February 2021

on focus list of Wikimedia project

0 references

Use and abuse of HOMA modeling

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of pancreatic β-cell function: review of methods and clinical applications

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AACE/ACE comprehensive diabetes management algorithm 2015.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular safety outcomes of new antidiabetic therapies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30431561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/MD.0000000000012633

0 references

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q60054208&oldid=2009993496"